Skip to main content
Journal of Patient-Reported Outcomes
Fig. 1 | Journal of Patient-Reported Outcomes

Fig. 1

From: Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease

Fig. 1

Study schematic. Note: The Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) was administered daily starting at the screening visit. All reference measures (Quality of Life in Neurological Disorders [Neuro-QoL] Fatigue item bank, Physician Global Assessment [PhGA], Patient Global Assessment [PGA], six-minute walk test [6MWT], Triple Timed Up and Go [3TUG] Test, Scale for the Assessment and Rating of Ataxia [SARA]), except for the “most bothersome” item, were administered during each of the study center (“Clinic”) visits. The Neuro-QoL Fatigue item bank was additionally administered during the nurse home visit at Week 6

Back to article page